“I don’t understand.”
“Whatever the code is, it’s the real message — it’s what the entire setup has been about. The source wanted the analyst purge to happen so he could send his coded message at the right time — and know it would be decoded by someone who wasn’t a double agent — namely you. He wanted us focused on cleaning up the analysts and delaying the fireworks until he could send this message. Had we known how thoroughly we had been compromised, we would have quarantined the field operatives first and sent Clocktower into total lock-down. We wouldn’t be having this conversation.”
“Yeah, but why even bother with a code? Why not send the message in the open like the previous communications?”
“It’s a good question. He must be under surveillance as well. Communicating whatever he’s trying to tell us in the open must have repercussions; maybe it would cause his death or speed up this terrorist attack. So whoever is watching him assumes we don’t know what the message says yet. That may be why they haven’t taken more of the cells down — they still think they can contain Clocktower,” David said.
“Makes sense.”
“It does, but one question still bothered me: why me?”
Josh thought for a moment. “Right, why not the director of Clocktower, all the other Clocktower Station Chiefs, or simply alert all the world’s intelligence agencies? They would have more far-reaching power to stop an attack. Maybe tipping them would start the attack early — just like sending the message in the open. Or… you could be in a unique position to stop the attack… or you know something.”
“Exactly. I mentioned earlier that I began investigating this super terrorist group before I joined Clocktower.” David stood, walked to the filing cabinet and withdrew two more folders. “I’m going to show you something I’ve been working on for over ten years, something I’ve never shown anyone, even Clocktower.”
CHAPTER 13
Interrogation Room C
West Jakarta Police Detention Center
Jakarta, Indonesia
Kate leaned back in the chair and thought about her options. She would have to tell tell the investigator how the trial had begun. Even if he didn’t believe it, she had to get it on the record in case they tried her. “Stop,” she said.
The man paused at the door.
Kate set her chair down and put her arms on the table. “There’s a very good reason why my trial adopted those children. There’s something you should understand. When I came to Jakarta, I expected to run this trial like any other trial in America. That was my first mistake. We failed… and we… changed our approach.”
The little man turned from the door, sat down, and listened as Kate described how she had spent weeks preparing for patient recruitment.
The trial had hired a Contract Research Organization (CRO) to run the trial, just as they would have in the US. In the US, pharmaceutical companies focus on developing a new drug or therapy, and when they have something promising, they hire a CRO to test it for them. The CROs find medical clinics with doctors interested in clinical research. The clinics, or sites, enroll willing patients into the trial, administer the new drug/therapy, then test them periodically for any health problems — adverse events. The CRO keeps close tabs on every site in the trial, reporting results to the sponsor/research organization, who makes their own reports to the FDA or governing body in countries around the world. The endgame was a trial with the desired therapeutic effect without any negative or adverse effects. It was a long road, and less than 1% of drugs that worked in the lab ever made it to pharmacy shelves.
There was only one problem: Jakarta, and Indonesia at large, had no autism clinics and only a handful of specialty practices focusing on developmental disorders. Those clinics weren’t experienced in clinical research — a dangerous situation for patients. The pharmaceutical industry was tiny in Indonesia, mostly because the market was small (Indonesia imported mostly generic drugs), so very few doctors were ever contacted about research.
The CRO came up with a novel concept: engage parents directly and run a clinic to administer the therapy. Kate and the trial’s lead investigator, Dr. John Helms, met with the CRO at length, searching for any alternatives. There were none. Kate urged Dr. Helms to move forward with the plan, and finally, he agreed.
They built a list of families within 100 miles of Jakarta that had any child on the autism spectrum. Kate booked an auditorium at one of the nicest hotels in town and invited the families to a presentation.